Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.2 USD | -2.80% | -2.80% | +10.64% |
Sales 2024 * | 200K 273K | Sales 2025 * | 200K 273K | Capitalization | 28.24M 38.6M |
---|---|---|---|---|---|
Net income 2024 * | -18M -24.6M | Net income 2025 * | -23M -31.44M | EV / Sales 2024 * | 141 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 141 x |
P/E ratio 2024 * |
-2
x | P/E ratio 2025 * |
-3.33
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.5% |
Latest transcript on Aprea Therapeutics, Inc.
1 day | -2.80% | ||
1 week | -2.80% | ||
Current month | -22.27% | ||
1 month | -14.33% | ||
6 months | +46.98% | ||
Current year | +10.64% |
Managers | Title | Age | Since |
---|---|---|---|
Oren Gilad
CEO | Chief Executive Officer | 56 | 22-04-30 |
John Hamill
DFI | Director of Finance/CFO | 60 | 23-01-29 |
Zeev Weiss
PRN | Corporate Officer/Principal | 62 | 22-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 14-12-31 |
John Henneman
BRD | Director/Board Member | 62 | 19-07-31 |
Rifat Pamukcu
BRD | Director/Board Member | 66 | 22-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 5.2 | -2.80% | 4,833 |
24-04-25 | 5.35 | +3.48% | 9,079 |
24-04-24 | 5.17 | -3.72% | 6,305 |
24-04-23 | 5.37 | +4.88% | 2,657 |
24-04-22 | 5.12 | -4.30% | 11,827 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.64% | 28.24M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- APRE Stock